reports
- ABGSC Healthcare Research
- Sten Gustafsson
Vedtægtsændringer
Vedtægtsændringer Selskabsmeddelelse nr. 13/2024 Der henvises til meddelelse nr. 12/2024 af 25. april 2024. Ændringerne i Columbus A/S’ vedtægter som følge af generalforsamlingens beslutning om at udvide bemyndigelserne i pkt. 5.1, 5.4 og 8.2 er d.d. registreret i Erhvervsstyrelsen. Der vedhæftes nye vedtægter. Ib Kunøe Søren Krogh KnudsenBestyrelsesformand Koncernchef Kontakt for yderligere information:Koncernchef, Søren Krogh Knudsen, tlf.: Vedhæftet fil
Amendment of Articles of Association
Amendment of Articles of Association Company announcement no. 13/2024 With reference to release no. 12/2024 of 25 April 2024, changes in Columbus A/S’ Articles of Association as a consequence of the decision made by the Annual General meeting to amend the authorizations in Art. 5.1, 5.4 and 8.2 have today been registered in the Danish Business Authority. New Articles of Association are attached. Ib Kunøe Søren Krogh KnudsenChairman of the Board CEO & President For further information, please contact:CEO & President, Søren Krogh Knudsen, Attac...
Passing of Columbus A/S’ Annual General Meeting and subsequent constit...
Passing of Columbus A/S’ Annual General Meeting and subsequent constitution of the Board of Directors Company announcement no. 12/2024 At Columbus A/S’ Annual General Meeting held on 25 April 2024, all proposals set out in the agenda were adopted, including the following; 1. The General Meeting took note of the Board of Directors’ report. 2. The Annual Report for 2023 was approved. 3. The Board of Directors’ proposal regarding distribution of profit was adopted, including payment of an ordinary dividend to the shareholders of DKK 0.125 per share of DKK 1.25 (nom), amounting to a total...
- Maria Vara
BONESUPPORT: debuts 2024 with strong financial results
Q1 2024 sales climbed by 54% (54% at CER) YoY and 7% QoQ, totalling SEK 184.4m. The US market, owing 77% of overall sales, was boosted by a 65% growth (65% at CER), with CERAMENT G being the major driver bringing SEK 92m sales (SEK 34.8m). EU showed a 27% YoY growth in sales, delivered by both prod
- ABGSC Healthcare Research
- Sten Gustafsson
- Patrik Ling
Arjo (Buy, TP: SEK58.00) - An in-line report
The Q1 results were fairly in line with our expectations, with the main deviation higher restructuring charges. Adjusted for this, EBIT was in line. Overall, organic growth was 4.3% YOY, in line with the full-year guidance of 3–5%. Arjo also provided an update on the Randomised Controlled Trial (RCT) for Wound Express, where data should be available in mid-2025. We reiterate our BUY, but have lowered our target price to SEK58 (60).
- Patrik Ling
Arjo (Buy, TP: SEK60.00) - Steady as she goes
We expect broadly stable trends in Q1 versus recent quarters, and forecast decent underlying growth, with patient-handling and pressure sore prevention again facing some headwinds but service and rental still going strong. We also expect a small negative impact from Red Sea-related logistics issues, but not enough to alter the overall picture. We reiterate our BUY and SEK60 target price.
Indkaldelse til ordinær generalforsamling
Indkaldelse til ordinær generalforsamling Selskabsmeddelelse nr. 11/2024 I henhold til vedtægternes pkt. 9.1 indkaldes til ordinær generalforsamling i Columbus A/S: Torsdag den 25. april 2024 kl. 10.00 hos Columbus, Lautrupvang 6, 2750 Ballerup Dagsorden: 1. Bestyrelsens beretning om selskabets virksomhed i det forløbne år. 2. Forelæggelse og godkendelse af årsrapport. 3. Beslutning om anvendelse af overskud eller dækning af underskud i henhold til den godkendte årsrapport. 4. Præsentation af og vejledende afstemning om vederlagsrapport. 5. Forslag om bemyndigelse af b...
Notice to convene Annual General Meeting
Notice to convene Annual General Meeting Company announcement no. 11/2024 According to Art. 9.1 of the Articles of Association, notice is hereby given of the Annual General Meeting of Columbus A/S to be held on: Thursday 25 April 2023 at 10.00 at Columbus, Lautrupvang 6, 2750 Ballerup Agenda: 1. Board of Directors’ report on the business of the Company during the past year. 2. Presentation and approval of the Annual Report. 3. Resolution on the appropriation of profit or covering of loss as recorded in the adopted Annual Report. 4. Presentation of and indicative ballot ...
Notification of transactions in Columbus A/S shares and related securi...
Notification of transactions in Columbus A/S shares and related securities by persons discharging managerial responsibilities and persons closely associated with them Company announcement no. 10/2024 In accordance with Article 19 (3) of the Market Abuse Regulation, Columbus A/S is required to disclose information regarding trading in Columbus A/S shares and/or related securities by persons discharging managerial responsibilities in Columbus A/S and/or persons closely associated with them. Please see the attached document for transaction details reported to Columbus. Ib Kunøe ...
Updated Financial Calendar 2024
Updated Financial Calendar 2024 Company announcement no. 9/2024 The Interim Report Q3 2024 will be published on 7 November 2024 instead of 6 November 2024. All other dates remain unchanged. Updated Financial Calendar for the rest of 2024: Annual General Meeting 25 April 2024Interim Report Q1 8 May 2024Interim Report Q2 22 August 2024Interim Report Q3 7 November 2024 After publication of financial statements the Company will conduct an investor presentation via a conference call and webcast. For details regarding the conference calls...
- Maria Vara
BONESUPPORT: CERAMENT doubles US TAM, on track to reach >SEK 2bn sales...
BONESUPPORT share price climbed by ~8% yesterday as of the FDA approval of CERAMENT G in open fracture/trauma following the 510(k) submission in Q4 2023. Although our estimates were aligned with the positive FDA outcome, we find it worth highlighting the impressive growth path behind and refreshing
Annual Report 2023
Annual Report 2023 Company announcement no. 8/2024 2023 financial performance: Continued solid organic growth Columbus’ revenue amounted to DKK 1,540m in 2023, corresponding to an increase of 11% and 15% adjusted for currency and acquisition. EBITDA increased by 28% to DKK 118m. All major Business Lines contributed to the revenue growth, especially our strategic Business Lines Data & Analytics and Customer Experience & Engagement showed continued rapid growth, delivering 30% and 49% respectively. Columbus’ largest Business Line, Dynamics also continued the strong development in 202...
- Maria Vara
BONESUPPORT: CERAMENT wins full FDA approval in Spine Fusion procedure...
Yesterday after the market close, BONESUPPORT announced that CERAMENT BONE VOID FILLER, the company's core synthetic bone graft technology, has been granted FDA approval on the Spine Interbody Fusion procedure, following the 510 (k) submission in Q1 2024. We are certainly surprised about the quick
Vedtægtsændringer
Vedtægtsændringer Meddelelse nr. 7/2024 22. februar 2024Vedtægtsændringer Selskabsmeddelelse nr. 7/2024 Der henvises til meddelelse nr. 5/2024 fra 22. februar 2024. Ændringen i Columbus A/S’ vedtægter som følge af bestyrelsesbeslutning om udstedelse af warrants i medfør af den bemyndigelse, der er indeholdt i vedtægternes pkt. 5.1. er registeret i Erhvervsstyrelsen. Der vedhæftes nye vedtægter. Ib Kunøe Søren Krogh KnudsenBestyrelsesformand Koncernchef Kontakt for yderligere information:Koncernchef, Søren Krogh Knudsen, tlf.: Ved...
Amendment of Articles of Association
Amendment of Articles of Association Company announcement no. 7/2024 With reference to release no. 5/2024 of 22 February 2024, changes in Columbus A/S’ Articles of Association as a consequence of the board resolution regarding issue of warrants in pursuance of the authorization in Section 5.1 in the Articles of Association, have been registered in the Danish Business Authority. New Articles of Association are attached. Ib Kunøe Søren Krogh KnudsenChairman of the Board CEO & President For further information, please contact:CEO & President, Søren Krog...
Notification of transactions in Columbus A/S shares and related securi...
Notification of transactions in Columbus A/S shares and related securities by persons discharging managerial responsibilities and persons closely associated with them Company announcement no. 6/2024 In accordance with Article 19 (3) of the Market Abuse Regulation, Columbus A/S is required to disclose information regarding trading in Columbus A/S shares and/or related securities by persons discharging managerial responsibilities in Columbus A/S and/or persons closely associated with them. Please see the attached document for transaction details reported to Columbus. Ib Kunøe ...
Incentive scheme
Incentive scheme Company announcement no. 5/2024 To strengthen Columbus A/S’ results and value creation for the company’s shareholders, retain and motivate senior executives, the Board of Directors has decided to exercise part of the authorization in Art. 5 in the company’s Articles of Association and issue 1,299,999 warrants, each of which entitles the recipient to subscribe for 1 share of nominal DKK 1.25, in Columbus A/S. If all warrants are exercised, the total capital increase in Columbus A/S will amount to DKK 1,624,998.75, corresponding to 1,299,999 shares of DKK 1.25. The e...
Swedish city court judgement fulfilled by M3CS
Swedish city court judgement fulfilled by M3CS Company announcement no. 4/2024 Reference is made to the judgement rendered by the Swedish city court on 24 January 2024 in favour of Columbus in which the court held that the company M3CS AB and its founders had acted unlawfully and were liable to pay damages and costs to Columbus in the range of SEK 43-45m. All parties’ subsequently appealed the judgement. On the date hereof, M3CS AB has fulfilled the judgement by payment of SEK 44,801,607 to Columbus and M3CS AB has withdrawn the appeal proceedings. It is expected that the founders of M3...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.